United Therapeutics Corporation (NASDAQ:UTHR) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

On April26, 2017, United Therapeutics Corporation issued a press
release setting forth its earnings for the quarter ended March31,
2017.

A copy of the press release is attached hereto as Exhibit99.1.

Item 9.01. Exhibits

This information shall not be deemed to be filed for the purposes
of Section18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to liability under that section, nor shall
it be deemed incorporated by reference into any filing under the
Securities Act of 1933, as amended, except as shall be expressly
set forth by specific reference in such filing.

(d) Exhibits

About United Therapeutics Corporation (NASDAQ:UTHR)

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). Its Prostacyclin Analogues lead product is Remodulin (treprostinil) Injection. It also includes Tyvaso (treprostinil) Inhalation Solution and Orenitram (treprostinil) Extended-Release Tablets. Its subsidiary is developing another oral prostacyclin analogue for the treatment of pulmonary arterial hypertension (PAH) called esuberaprost. Its PDE-5 inhibitor is Adcirca (tadalafil) tablets are indicated for the treatment of PAH. Its Unituxin (dinutuximab) Injection in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid is indicated for the treatment of pediatric patients with neuroblastoma.

United Therapeutics Corporation (NASDAQ:UTHR) Recent Trading Information

United Therapeutics Corporation (NASDAQ:UTHR) closed its last trading session down -0.97 at 121.74 with 694,378 shares trading hands.